↓ Skip to main content

Lipid-lowering for peripheral arterial disease of the lower limb

Overview of attention for article published in Cochrane database of systematic reviews, October 2007
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
116 Dimensions

Readers on

mendeley
148 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Lipid-lowering for peripheral arterial disease of the lower limb
Published in
Cochrane database of systematic reviews, October 2007
DOI 10.1002/14651858.cd000123.pub2
Pubmed ID
Authors

Phyu Phyu Aung, Heather Maxwell, Ruth G Jepson, Jackie Price, Gillian C Leng

Abstract

Raised lipid levels, including cholesterol, are important risk factors in the development of lower limb arterial disease (atherosclerosis). The objective of this review was to assess the effects of lipid lowering therapy in patients with lower limb atherosclerosis. The reviewers searched the Cochrane Peripheral Vascular Diseases Group trials register, Embase, reference lists of relevant articles, and contacted trial investigators in Europe and pharmaceutical companies. Randomised trials of lipid-lowering therapy in patients with lower limb atherosclerosis. The main outcomes were mortality, non-fatal events, direct tests of disease progression, indirect measurements of disease, and subjective measures. Two reviewers extracted data and assessed trial quality independently. The reviewers contacted investigators to obtain information needed for the review that could not be found in published reports. There were nine eligible trials, but two were excluded because of poor methodology. The seven remaining trials involved a total of 698 participants from seven different countries. Men and women participated in all but one trial and were generally middle aged to elderly. The follow-up period varied from four months to three years. The overall quality of the included trials was high. The trials were heterogeneous in terms of inclusion criteria, type of drugs used and outcomes measured. Lipid-lowering therapy produced a marked but non-significant reduction in mortality (odds ratio 0.21, 95% confidence interval 0. 03 to 1.17), but little change in non-fatal events (odds ratio 1.21, 95% confidence interval 0.80 to 1.83). In two trials there was a significant overall reduction in disease progression on angiogram (odds ratio 0.47, 95% confidence interval 0.29 to 0.77). The changes in ankle brachial pressure index and walking distance were inconsistent, although trials showed a general improvement in symptoms that could not be combined in a meta-analysis. Side effects were generally mild, with the exceptions of liver toxicity produced by betapyridil and the adverse effect of probucol on lipoprotein profile. Lipid-lowering therapy may be useful in preventing deterioration of underlying disease and alleviating symptoms. These results cannot determine whether one lipid-lowering regimen is better than another.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 2%
Switzerland 1 <1%
Spain 1 <1%
United States 1 <1%
Unknown 142 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 33 22%
Student > Master 24 16%
Student > Bachelor 18 12%
Student > Postgraduate 18 12%
Student > Ph. D. Student 15 10%
Other 39 26%
Unknown 1 <1%
Readers by discipline Count As %
Medicine and Dentistry 88 59%
Unspecified 21 14%
Agricultural and Biological Sciences 10 7%
Nursing and Health Professions 7 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Other 16 11%
Unknown 1 <1%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2019.
All research outputs
#12,254,592
of 13,851,361 outputs
Outputs from Cochrane database of systematic reviews
#10,412
of 10,735 outputs
Outputs of similar age
#220,394
of 263,361 outputs
Outputs of similar age from Cochrane database of systematic reviews
#182
of 185 outputs
Altmetric has tracked 13,851,361 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,735 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,361 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 185 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.